RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
Open Access
- 15 July 2020
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 52 (3), 973-986
- https://doi.org/10.4143/crt.2019.726
Abstract
Purpose Triple-negative breast cancer (TNBC) is highly malignant and has poor prognosis and a high mortality rate. The lack of effective therapy has spurred our investigation of new targets for treating this malignant cancer. Here, we identified RON (macrophage-stimulating 1 receptor) and MET (MET proto-oncogene, receptor tyrosine kinase) as a prognostic biomarker and therapeutic targets for potential TNBC treatment. Materials and Methods We analyzed RON and MET expression in 187 primary TNBC clinical samples with immunohistochemistry. We validated the targeted therapeutic effects of RON and MET in TNBC using three tyrosine kinase inhibitors (TKIs): BMS-777607, INCB28060, and tivantinib. The preclinical therapeutic efficacy of the TKIs was mainly estimated using a TNBC xenograft model. Results Patients with TNBC had widespread, abnormal expression of RON and MET. There was RON overexpression, MET overexpression, and RON and MET co-overexpression in 63 (33.7%), 63 (33.7%), and 43 cases (23.0%), respectively, which had poor prognosis and short survival. In vivo, the TKI targeting RON ant MET inhibited the activation of the downstream signaling molecules, inhibited TNBC cell migration and proliferation, and increased TNBC cell apoptosis; in the xenograft model, they significantly inhibited tumor growth and shrank tumor volumes. The TKI targeting RON and Met, such as BMS-777607 and tivantinib, yielded stronger anti-tumor effects than INCB28060. Conclusion RON and MET co-overexpression can be significant pathological characteristics in TNBC for poor prognosis. TKIs targeting RON and MET have stronger drug development potential for treating TNBC.Keywords
Funding Information
- National Natural Science Foundation of China (81872883)
- Zhejiang Major Medical Health & Sciences Technology Foundation Projects (WKJ-ZJ-13, 2014C33204)
- Zhejiang Provincial Natural Science Foundation (LY18H160014)
This publication has 33 references indexed in Scilit:
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3Clinical Cancer Research, 2011
- Distinct Involvement of the Gab1 and Grb2 Adaptor Proteins in Signal Transduction by the Related Receptor Tyrosine Kinases RON and METOnline Journal of Public Health Informatics, 2011
- Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancerProceedings of the National Academy of Sciences of the United States of America, 2009
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancerProceedings of the National Academy of Sciences of the United States of America, 2009
- Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase SuperfamilyJournal of Medicinal Chemistry, 2009
- Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cellsThe Journal of Pathology, 2007
- Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissueHistopathology, 2007
- Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer PatientsClinical Cancer Research, 2005
- Cross-talk between the proto-oncogenes Met and RonOncogene, 2000
- Overexpression of the RON gene in human breast carcinomaOncogene, 1998